miR-660-5p antagonist

miR-660-5p antagonist is a target-specific oligonucleotide therapeutic designed to inhibit the activity of microRNA-660-5p (miR-660-5p). In the context of liver disease, miR-660-5p is upregulated during the progression of liver fibrosis. Antagonism of miR-660-5p has been shown to attenuate steatohepatitis-related liver fibrosis in preclinical models, which is associated with the regulation of the FGF9–FGF21 axis and transcriptional reprogramming of hepatocytes. Additionally, miR-660-5p acts as an oncogenic microRNA (oncomiR) in various cancers, including hepatocellular carcinoma (HCC) and breast cancer, where its inhibition reduces cell proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT) by restoring target genes such as YWHAH and TMEM41B.

Other names

hsa-miR-660-5p antagonisthsa-miR660-5p antagonisthsa-miR 660-5p antagonisthsa-miR-660-5p inhibitorhsa-miR660-5p inhibitorhsa-miR 660-5p inhibitormiR-660-5p inhibitormiR660-5p inhibitormiR 660-5p inhibitormicroRNA-660-5p antagonistmicroRNA660-5p antagonistmicroRNA 660-5p antagonistmicroRNA-660-5p inhibitormicroRNA660-5p inhibitormicroRNA 660-5p inhibitor